“In April, an expert advisory panel for the FDA voted unanimously to recommend Epidiolex’s approval and determined that ‘CBD has a negligible abuse potential.’ The DEA did not immediately respond to Ars’ request for comment. But GW said it expects that the DEA will reschedule CBD within 90 days.”

Read more: https://arstechnica.com/science/2018/06/fda-approves-first-marijuana-derived-drug-and-it-may-spark-dea-rescheduling/

Did you like this?
Tip Freedomwat.ch Staff with Bitcoin

Donate via Installed Wallet Copy